Idenix Pharmaceuticals (IDIX) Higher After Positive Phase II Study Results
More News related to IDIX
- Idenix Pharmaceuticals to Present at the Third Annual JMP Securities Healthcare Focus Conference
- Idenix Pharmaceuticals (IDIX) Files $100M Offering
- Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
- Idenix Pharmaceuticals to Present at the 2008 Thomas Weisel Healthcare Conference
- Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
More News related to FDA
- Angiotech (ANPI) Reports Boston Scientific (BSX) Receives FDA Approval to Market its second-generation TAXUS Liberte
- AstraZeneca (AZN) Receives FDA Approval for Once-Daily SEROQUEL XR(R)
- Medicis (MRX) Receives FDA Approval of PMA Supplement for RESTYLANE(R)
- Biogen Idec (BIIB) Said Baminercept Trial Failed To Meet Primary Endpoint
Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) is 20% higher in pre-open trading after the company announced results from a phase II study designed to evaluate triple combination therapy, consisting of valopicitabine (NM283), Idenix's lead drug candidate for the treatment of hepatitis C, pegylated interferon and ribavirin compared to pegylated interferon and ribavirin, the current standard of care, in patients infected with the genotype-1 strain of the hepatitis C virus (HCV).
The company said the study demonstrated no pharmacokinetic or pharmacodynamic drug-drug interaction between valopicitabine and ribavirin. The triple combination showed consistently higher rates of HCV PCR-negativity, defined as serum HCV RNA levels below 20 copies/mL, compared to the standard of care at every point analyzed in this study. Additionally, the tolerability of the triple combination was satisfactory, with only three discontinuations from the study.
Related Categories
FDAMomentum Movers
Stocks Mentioned
-0.37Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
